Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

Yuhan Corporation CEO, Wook-Je Cho said, "We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen our anticancer drug pipeline in the future." Yuhan Corporation CEO, Wook-Je Cho said, "We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen our anticancer...

Yuhan Corporation CEO, Wook-Je Cho said, "We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen our anticancer drug pipeline in the future."

Anna Jo, CEO of J INTS BIO, said, "JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations." And it can become the most promising Best-in-Class TKI therapy in this field."

Meanwhile, Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022, respectively, and holds a 14.8% stake in the company.

Photo - https://mma.prnewswire.com/media/2089040/image_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/yuhan-corporation-and-j-ints-bio-inked-a-licensing-agreement-for-a-new-drug-candidate-targeting-her2-nsclc-301838158.html